methyl 4-((4-amino-3,5-dimethyl-1H-pyrazol-1-yl)methyl)benzoate

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: methyl 4-((4-amino-3,5-dimethyl-1H-pyrazol-1-yl)methyl)benzoate
• 英文别名: Methyl 4-[(4-amino-3,5-dimethyl-1H-pyrazol-1-yl)methyl]benzoate；methyl 4-[(4-amino-3,5-dimethylpyrazol-1-yl)methyl]benzoate
• 化学式: C₁₄H₁₇N₃O₂
• 分子量: 259.308
• InChiKey: NDRVJKSRIIFODA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  19
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  70.1
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  methyl 4-((4-amino-3,5-dimethyl-1H-pyrazol-1-yl)methyl)benzoate 在 氨 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 作用下， 以 甲醇 、 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 28.0h， 生成 N-(1-(4-carbamoylbenzyl)-3,5-dimethyl-1H-pyrazol-4-yl)-4-(phenoxymethyl)benzamide
  参考文献：
  名称：

  N-(1-Benzyl-3,5-dimethyl-1H-pyrazol-4-yl)benzamides: Antiproliferative Activity and Effects on mTORC1 and Autophagy

  摘要：

  Guided by antiproliferative activity in MIA PaCa-2 cells, we have performed preliminary structure activity relationship studies on N-(1-benzyl-3,5-dimethyl-1H-pyrazol-4-yl)benzamides. Two selected compounds showed submicromolar antiproliferative activity and good metabolic stability. Both compounds reduced mTORC1 activity and increased autophagy at the basal level. In addition, they disrupted autophagic flux by interfering with mTORC1 reactivation and clearance of LC3-II under starvation/refeed conditions, as evidenced by accumulation of LC3-II and abnormal LC3 labeled punctae. Therefore, N-(1-benzyl-3,5-dimethyl-1H-pyrazol-4-yl)benzamides may represent a new class of autophagy modulators that possesses potent anticancer activity and potentially a novel mechanism of action.

  DOI：

  10.1021/acsmedchemlett.6b00392
• 作为产物：
  描述：

  3,5-二甲基-4-硝基吡唑 在 sodium tetrahydroborate 、 nickel(II) chloride hexahydrate 、 caesium carbonate 作用下， 以 甲醇 、 N,N-二甲基甲酰胺 为溶剂， 反应 27.0h， 生成 methyl 4-((4-amino-3,5-dimethyl-1H-pyrazol-1-yl)methyl)benzoate
  参考文献：
  名称：

  N-(1-Benzyl-3,5-dimethyl-1H-pyrazol-4-yl)benzamides: Antiproliferative Activity and Effects on mTORC1 and Autophagy

  摘要：

  Guided by antiproliferative activity in MIA PaCa-2 cells, we have performed preliminary structure activity relationship studies on N-(1-benzyl-3,5-dimethyl-1H-pyrazol-4-yl)benzamides. Two selected compounds showed submicromolar antiproliferative activity and good metabolic stability. Both compounds reduced mTORC1 activity and increased autophagy at the basal level. In addition, they disrupted autophagic flux by interfering with mTORC1 reactivation and clearance of LC3-II under starvation/refeed conditions, as evidenced by accumulation of LC3-II and abnormal LC3 labeled punctae. Therefore, N-(1-benzyl-3,5-dimethyl-1H-pyrazol-4-yl)benzamides may represent a new class of autophagy modulators that possesses potent anticancer activity and potentially a novel mechanism of action.

  DOI：

  10.1021/acsmedchemlett.6b00392

文献信息

• [EN] GLUCOSE TRANSPORT INHIBITORS<br/>[FR] INHIBITEURS DE TRANSPORT DU GLUCOSE
  申请人：BAYER PHARMA AG

  公开号：WO2015091428A1

  公开（公告）日：2015-06-25

  The present invention relates to chemical compounds that selectively inhibit glucose transporter 1 (GLUT1), to methods of preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds, to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, as well as to intermediate compounds useful in the preparation of said compounds.

  本发明涉及选择性抑制葡萄糖转运蛋白1（GLUT1）的化合物，涉及制备该类化合物的方法，包括含有该类化合物的药物组合物和药物组合物，以及利用该类化合物制造用于治疗或预防疾病的药物组合物的用途，还涉及在制备该类化合物中有用的中间体化合物。
• ANTICANCER COMPOUNDS
  申请人：REGENTS OF THE UNIVERSITY OF MINNESOTA

  公开号：US20180071258A1

  公开（公告）日：2018-03-15

  The invention provides compounds having the general formula I: and salts thereof, wherein the variables R A , R B , R C , L 1 , L 2 , L 3 , A, B, C, X, Y, Z, E, m, n, and p have the meaning as described herein, and compositions containing such compounds and methods for using such compounds and compositions.

  这项发明提供了具有一般式I的化合物及其盐，其中变量RA、RB、RC、L1、L2、L3、A、B、C、X、Y、Z、E、m、n和p的含义如本文所述，以及含有这种化合物的组合物、使用这种化合物和组合物的方法。
• Anticancer compounds
  申请人：REGENTS OF THE UNIVERSITY OF MINNESOTA

  公开号：US10357477B2

  公开（公告）日：2019-07-23

  The invention provides compounds having the general formula I: and salts thereof, wherein the variables RA, RB, RC, L1, L2, L3, A, B, C, X, Y, Z, E, m, n, and p have the meaning as described herein, and compositions containing such compounds and methods for using such compounds and compositions.

  本发明提供了具有通式 I 的化合物： 及其盐类，其中变量 RA、RB、RC、L1、L2、L3、A、B、C、X、Y、Z、E、m、n 和 p 的含义如本文所述，以及含有此类化合物的组合物和使用此类化合物及组合物的方法。
• GLUCOSE TRANSPORT INHIBITORS
  申请人：Bayer Pharma Aktiengesellschaft

  公开号：EP3083598A1

  公开（公告）日：2016-10-26